Dear All,
Here is a brief Bio of our speaker at 12pm in ENGR 1602 –
|
BIOGRAPHICAL SKETCH Provide the following information for the key personnel and other significant contributors. |
||||
|
|
||||
|
NAME Eugene F. Civillico |
POSITION TITLE Health Physicist |
|||
|
eRA COMMONS USER NAME CIVILLICO |
||||
|
EDUCATION/TRAINING |
||||
|
INSTITUTION AND LOCATION |
DEGREE (if applicable) |
YEAR(s) |
FIELD OF STUDY |
|
|
Harvard College, Cambridge, MA |
B.A. |
June 1998 |
Biology |
|
|
University of Pennsylvania School of Medicine |
Ph.D. |
May 2006 |
Neuroscience |
|
|
Princeton University |
Postdoctoral |
2006-2009 |
Neuroscience |
|
A. Personal Statement
I lead a research group within the Division of Biomedical Physics in FDA/CDRH’s Office of Science and Engineering Laboratories. We focus on common problems in the translation of novel neurotechnology and neurorehabilitation
concepts into successful clinical solutions. Recently, we have become interested in the disconnect between the designed technical capabilities of next-generation prosthetics and their ability to solve medical problems, as defined by their users and the payer/provider
community. This topic touches on an issue of rapidly expanding importance for CDRH and the biomedical stakeholder community – namely, the role of the patient’s voice in medical product development and regulatory approval. Accordingly, I will be very pleased
to assist with the work being proposed, which could result in one of the largest data sets ever collected on the subject of what impairments are most burdensome to potential prosthesis users, and how their views could influence their risk tolerance.
In addition to my research efforts, I provide subject matter expert consulting reviews for neurological and physical medicine device submissions to CDRH’s Office of Device Evaluation, which performs premarket
review of new medical devices. I also work with the Office of the CDRH Center Director to identify and promote mission-relevant research directions for our intramural labs. These experiences at CDRH have given me the knowledge necessary to orient research
output in an impactful direction. By building on the momentum of various public and private patient-centered benefit/risk assessment initiatives, I will help to ensure that the results of the proposed work are consistent with FDA guidelines on quantifying
patient preferences, and are communicated to all relevant stakeholders for maximum impact. In addition, my experience in quantitative methods development as a systems neuroscientist will help me contribute to the proposed work.
B. Positions and Honors
Mentor: Samuel S.-H. Wang, Ph.D.